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Abstract
Background: Greater transparency, including sharing of patient-level data for further research, is an increasingly
important topic for organisations who sponsor, fund and conduct clinical trials. This is a major paradigm shift with
the aim of maximising the value of patient-level data from clinical trials for the benefit of future patients and
society. We consider the analysis of shared clinical trial data in three broad categories: (1) reanalysis - further
investigation of the efficacy and safety of the randomized intervention, (2) meta-analysis, and (3) supplemental
analysis for a research question that is not directly assessing the randomized intervention.
Discussion: In order to support appropriate interpretation and limit the risk of misleading findings, analysis of
shared clinical trial data should have a pre-specified analysis plan. However, it is not generally possible to limit bias
and control multiplicity to the extent that is possible in the original trial design, conduct and analysis, and this should
be acknowledged and taken into account when interpreting results. We highlight a number of areas where specific
considerations arise in planning, conducting, interpreting and reporting analyses of shared clinical trial data. A key issue
is that that these analyses essentially share many of the limitations of any post hoc analyses beyond the original
specified analyses. The use of individual patient data in meta-analysis can provide increased precision and reduce
bias. Supplemental analyses are subject to many of the same issues that arise in broader epidemiological analyses.
Specific discussion topics are addressed within each of these areas.
Summary: Increased provision of patient-level data from industry and academic-led clinical trials for secondary
research can benefit future patients and society. Responsible data sharing, including transparency of the research
objectives, analysis plans and of the results will support appropriate interpretation and help to address the risk of
misleading results and avoid unfounded health scares.
Background
Greater transparency, including sharing of patient-level
data for further research, is an increasingly important
topic for the pharmaceutical industry and other organi-
sations (government agencies, academia, charities etc.)
who sponsor, fund and conduct clinical trials. Drivers of
these changes have come from several sources – for ex-
ample, the scientific community/academia [1, 2], regula-
tors [3–5], and the pharmaceutical industry [6]. This
paradigm shift aims to maximise the value of patient-
level data from clinical trials for the benefit of future
patients and society, by sharing clinical trial data for sec-
ondary research. However, the risk of publication of mis-
leading results and unfounded health scares has also
been recognized by those advocating increased access
[3]; responsible data sharing, including transparency of
the research requests, objectives, analysis plans and re-
sults will support appropriate interpretation and help to
mitigate this risk. This article is one of five related arti-
cles in this journal, resulting from a working group
formed by EFSPI (European Federation of Statisticians
in the Pharmaceutical Industry) and PSI (Statisticians in
the Pharmaceutical Industry) to examine various aspects
of transparency of patient-level data from clinical trials.
The focus here is on analysis of shared data from trials
sponsored by pharmaceutical companies, but the princi-
ples discussed also apply more broadly.
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We will consider analysis of shared clinical data within
three broad categories:
i. Reanalysis: further investigation of the efficacy and
safety of the randomized intervention using
individual patient-level data from a clinical trial, e.g.
 Using a new measure of benefit or risk that can
be derived from the available data
 Exploring the impact of analysis assumptions
made, such as the handling of missing data
 Verification of the results in the original study
report or publication
ii. Meta-analysis: further investigation of the efficacy
and safety of one or more randomized interventions
using individual patient-level data from several
clinical trials, e.g.
 meta-analysis to learn more about an intervention
by pooling several trials including the same
comparison
 network meta-analysis to learn more about the
relative effect of various interventions by making
indirect comparisons across several trials with
different comparators
iii. Supplemental analysis: use of individual patient-level
data from a clinical trial for a research question that is
not directly assessing the randomized intervention, e.g.
 exploring prognostic factors and characterising
disease evolution over time
 evaluating new statistical methods
 understanding relationships between endpoints
 gaining information to inform the design of a
future study
This paper will lay out some key considerations rele-
vant to planning, conducting, interpreting and reporting
analyses of shared clinical trial data, and then address is-
sues specifically relevant to each of the categories above.
Existing methodological guidelines for analysis of ran-
domized trials, meta-analysis of randomized trials, or
analysis of epidemiological data can be used for general
guidance for best practice on what analysis features
should be pre-specified and how the results should be
reported. This debate paper aims to highlight specific
areas where additional considerations may arise.
Discussion
General considerations for the analysis of shared clinical
trial data
The original analysis of a clinical trial data provides
protection against bias and misinterpretation by pre-
specification of the objectives and the analysis methods.
In order to support appropriate interpretation and limit
the risk of misleading findings, analyses of shared clin-
ical trial data should also have a pre-specified analysis
plan. However, it is not generally possible to limit bias
and control multiplicity to the extent that is possible in
the original trial design, conduct and analysis, and this
should be acknowledged and taken into account when
interpreting the results of analyses of shared clinical trial
data. The nature of the potential biases and sources of
multiplicity will differ between the scenarios considered,
and so this topic is addressed in more detail in the rele-
vant sections below.
Planning the research
The data requestor should establish the data holder’s ex-
pectations of the data sharing process, including the
process of handling queries at the planning and conduct
stages, and any expectations for the data requestor to in-
form the data holder of their findings and publication
plans. Some data holders may offer a specific point of
contact who can provide advice, whilst others may have
established systems for dealing with any queries (e.g.
ClinicalStudyDataRequest.com). The data holder will
generally be able to provide documentation which will
help the data requestor understand the trial design, con-
duct and analysis methods (including the protocol, stat-
istical analysis plan and reports), and the data structures
(such as annotated case report forms and database speci-
fications). Some data holders may be willing to share
some or all of this documentation with a data requestor
to support their planning, and some will provide full
documentation only once a research proposal has been
agreed. Requestors should ensure that they set aside
time for navigating the access process and be aware that
they will be required to agree to a legal data use agree-
ment. Further guidance on important points for data re-
questors to consider and guidance on the most efficient
way to obtain the information needed is covered in a
companion article in this collection [7].
The data requestor should define and document the
question of interest, hypotheses, and the planned statis-
tical analyses before accessing the data. While the design
of the study and the raw data collected are fixed, there
are many aspects of the planed analysis which can be
pre-specified. An analysis plan should generally include
details of:
 The main objectives
 The populations and variables to be analysed,
including details of any subjects and data which
will be excluded
 Statistical tests or models to be used, including
covariates where applicable
 Any data transformations to be used, and how any
missing data or outliers will be handled
 Any planned adjustment of significance and
confidence levels
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 Any planned sensitivity analyses to explore the
robustness of the results
 Any planned investigation of subgroups
Analytical methods that are inherently exploratory in
nature such as data mining can also be of value in this
context, provided that the intended purpose and scope
are clearly defined.
At the planning stage, dialogue with the data holder is
recommended to ensure that the data being requested
can support the intended analyses. For example a data
requestor may need to know whether planned covariates
will be available in the datasets supplied, i.e. that the in-
formation has been collected at the required level of de-
tail, and whether it will be subject to any redaction due
to data privacy provisions. Many data holders will rou-
tinely apply a number of de-identification techniques
prior to sharing individual patient level data [8]. These
commonly include masking absolute dates from datasets
and/or retaining information about the relative timing of
events only, and censoring ages, for example above
89 years. In some cases, data privacy rules in different
regions may lead to selected patients being removed en-
tirely from the datasets. The impact of this should be
considered and discussed with the data holder where ne-
cessary. For example, if the question of interest involves
the seasonal pattern of events such as asthma exacerba-
tions, then the data requestor should discuss with the
data holder whether data could be provided that retain
sufficient information for this to be further investigated.
Ideally the protocol and analysis plan for research on
shared clinical trial data should be publically docu-
mented. This helps to prevent unplanned duplication of
research, and allows the level of pre-specification of ana-
lyses to be subsequently verified. In some cases, the data
holder may make provisions for this as part of the data
request process, or there may be opportunities such as
the PROSPERO database [9] or Cochrane library for
meta-analysis protocols, or within journals which are in-
creasingly providing opportunities for the publication of
research protocols.
Conducting the analyses
Once a data requestor obtains access to the data, a
key step prior to performing analyses is to understand
the data including the data structure, formats, coding
used, the meaning of each variable in the data set,
and establishing which variables reflect ‘raw’ data
from the case report forms, medical notes or direct
results of trial assessments, and which variables re-
flect ‘derived’ variables where algorithms have been
applied. Dialogue with the data holder may be needed
during conduct of the analyses, particularly for older
trials where the complete documentation may not be
available, or may be lacking in detail.
It is best practice for the data recipient to replicate the
primary analysis of the primary endpoint of the study
where this is possible. This allows the data recipient to
increase their confidence in understanding the structure
and format of the data set before proceeding to conduct
their planned analyses. Where an exact replication of the
original results will not be possible due to data privacy
provisions, the data recipient may wish to request that
the data holder provides the results obtained by them
when the planned primary analysis is run on the shared
data, in order that this check can still be applied.
The data recipient should also check that the proposed
analyses can be carried out. If necessary, depending on
the structure of the data received or on initial explora-
tions of the data, amendments could be made to the
analysis plan. There should be clear documentation of
any amendments to the methods and analyses, including
details of the scientific rationale and the timing of
changes relative to access to the datasets. If a data re-
cipient wishes to make a significant expansion to the
scope of the research, such as the consideration of add-
itional derived endpoints, the data holder should be con-
tacted to submit an expanded request.
Interpretation
The data recipient should consider any potential sources
of bias in the analyses due to features of the design and
conduct of the trial, and take these into account when
interpreting the results of further analyses, such as com-
bining blinded trials with open trials in a meta-analysis
or using hazard ratios to combine trials where one or
more trials have pronounced non-proportional hazards
and have used a different summary measure.
As with the original analyses, clinical relevance needs
to be considered as well as statistical significance; sensi-
tivity analyses may also prove useful to help demonstrate
the robustness of the results.
If a data recipient identifies a potential new safety sig-
nal then it is important that they immediately inform
any parties responsible for the intervention. This would
generally include the sponsor of the trial. For licenced
medicines, the market authorization holder will have
processes in place to ensure appropriate consideration
and handling of potentially important new safety find-
ings, including communication to the relevant compe-
tent authorities (EMA, FDA, etc.) where necessary.
Reporting
For full transparency and to avoid publication bias, data
requestors conducting analyses on shared clinical trial
data must make all attempts to publish all results of the
pre-specified analyses in a peer reviewed journal,
Hollis et al. BMC Medical Research Methodology 2016, 16(Suppl 1):76 Page 17 of 43
regardless of the findings. In line with good trial
reporting practice [10], all publications should state
that the results were generated after the completion
of the original clinical trial analysis and reporting, in-
cluding references to publications containing the re-
sults from the original analyses. Any new objectives
or analyses that were added after access to the data
was obtained should be clearly identified as such and
interpreted appropriately in light of this.
If the trial is registered on suitable clinical trials
registries, the corresponding identifier should be in-
cluded in any publications (e.g. ClinicalTrials.gov and
“NCT Number”). There is an automatic identification
process whereby publications indexed in MEDLINE
are linked to the trial record [11].
Some analyses of shared clinical trial data may not be
of great interest to journals, e.g. further analyses of the
efficacy or safety of any intervention that provide little
new clinically relevant information, or a simple analysis
to support sample sizing. Either the data recipient’s or
the data requestor’s institution may have mechanisms
which could be used for posting such information in the
public domain as reports or “white papers”.
Specific considerations for reanalysis
Overview of potential biases and sources of multiplicity
ICH (International Council for Harmonisation of Tech-
nical Requirements for Pharmaceuticals for Human Use)
E9 ‘Statistical Principles for Clinical Trials’ is a key guid-
ance for statistical methodology applied to clinical trials
for marketing applications demonstrating the safety and
efficacy of medicinal products [12]. Throughout the ICH
E9 guidance there is emphasis on the use of pre-
specification to protect against multiplicity of methods
and interpretation and of blind review (checking of data
prior to the breaking of the blind) in order that unbiased
decisions about the analysis methods can be made. For
confirmatory trials of medicines, key statistical methods
will be defined in the protocol prior to initiation of the
trial, and a statistical analysis plan will be written prior to
un-blinding of the data. The analysis plan will provide de-
tails of the analysis populations, the derivation of vari-
ables, and the statistical methods, and document any
changes from the analyses planned in the protocol. The
level of detail contained in a confirmatory trial analysis
plan has increased over recent decades, and it is now
common for these plans to be from tens to hundreds of
pages long. Multiplicity is addressed through the hierarchy
of primary, secondary and exploratory objectives. Formal
control of the type 1 error may be specified across mul-
tiple primary and secondary variables, multiple compari-
sons of treatments, and repeated evaluations over time.
This framework of pre-planned analyses supports appro-
priate interpretation of the results. There will also be an
evaluation of the robustness of the results and primary
conclusions of the trial, examining the sensitivity of the
overall conclusions to various limitations of the data, as-
sumptions made, and choice of analysis methods. Key sen-
sitivity analyses will be pre-specified in the analysis plan,
but the need for further exploratory analyses may become
apparent on further examination of the data. Even in the
presence of a thorough analysis plan, unexpected findings
can lead to a need for post-hoc analyses. Regardless of
what motivates such post-hoc analyses, they are likely to
produce biased results, and introduce multiplicity issues
that cannot easily be controlled. Publication bias is also
more likely to apply to post-hoc analyses.
Analyses of shared clinical trial data are essentially post
hoc analyses, and therefore of exploratory, rather than
confirmatory, value. While new medical insights can be
generated from post hoc analyses, it will be especially im-
portant to consider broader factors when interpreting
the results and discussing whether causation might be
concluded from an observed association [13].
Some data recipients may have a direct interest in re-
futing the interpretation of the original analyses. This
could be a source of bias, but would still be best dealt
with through the usual scientific process of evaluation of
evidence which would include the application of the rec-
ommendations for planning, conduct, interpretation and
reporting described in this debate article. However, even
when data recipients do not have any such direct
agenda, there is still increased potential for bias in ana-
lyses of shared clinical trial data compared to the ori-
ginal analyses conducted. The original results will
generally have been published prior to data being shared
and so the data recipient is likely to be aware of the
main findings and even some information such as the
amount and nature of missing data in each randomized
group. As such, further analyses should generally be
considered subject to potential bias in the same way that
post hoc analyses performed by the original researchers
would be. The interpretation of reanalysis can be
strengthened by explicitly stating in the research pro-
posal and analysis plan the basis for any differences from
the original analysis methods, and the extent to which
information relating to the likely impact is already
known.
Subgroup analyses
The issues in interpretation of subgroup analyses beyond
those planned in the original study analysis apply to both
post hoc analyses by the original researchers, and to ana-
lyses of shared clinical trial data. There is interest from
regulatory authorities, patients, medical practitioners
and Health Technology Assessors in whether the effects
of a medicine are consistent across a range of patient
subsets. However, the dangers of over-interpreting
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findings from exploratory subgroups including the risk
of false positives and the low power of interaction tests
are well documented in the literature [14, 15]. ICH E9
[12] notes that in most case subgroups investigations are
exploratory in nature, and should be interpreted cau-
tiously. This also applies to an investigation of a sub-
group in an analysis of shared clinical trial data, and
the potential for significant bias needs to be made clear
when interpreting and reporting the results [16, 17].
The biological plausibility of a subgroup effect should
be considered [13]. Subgroup analyses should not be
fishing expeditions to find a group where the treatment
is effective or ineffective.
Applying alternative analytical approaches
Since the clinical trial data were collected specifically to
address the objectives of the original protocol, there may
be limitations in the data being able to fully address add-
itional clinical questions of interest. This may be due
broadly to the way participants were selected or specific-
ally due to the way in which data were recorded or
coded for analysis. For example, a new analysis may be
planned where the original outcome definition is modi-
fied to only include events which led to a specific med-
ical intervention. The clinical relevance of this new
definition should be justified, and the limitations of
using medical intervention data which were not col-
lected for this purpose should be considered. Attenu-
ation of the estimated effect of the intervention could
occur if there is any misclassification of the medical
intervention. Also, the precision could be reduced, for
example if a new outcome leads to fewer events.
Attention should be paid to how missing data will be
handled, clearly distinguishing whether the missing data
are already inherent in the original study data, and thus
have been treated or reported in the original Clinical
Study Report (CSR), or the missing data are due to the
data sharing and data transfer process, such as the
categorization of age. In the first case missing data could
be treated according to predefined imputation rules
either as given in the original protocol or Statistical Ana-
lysis Plan (SAP), or according to newly defined rules in
the data recipients’ analysis plan. In either case, sensitiv-
ity analyses are recommended to evaluate the possible
impact of the missing data and the methods used to
handle missing data on the outcome in comparison to
the original results. Sensitivity analyses have to be
planned and conducted carefully – (e.g. Thabane et al
[18]). Methodology has evolved in recent years, for ex-
ample Morris et al [19] and Mallinckrodt et al [20] give
good examples of dealing with missing data assumptions
within a sensitivity analyses framework.
Additionally, if the original analysis was carried out
using a statistical model with covariates, it may be
interesting to explore the effect of a different set of co-
variates or of fitting no covariates. However, when chan-
ging the covariates in a model, consideration should be
given to the biological plausibility of the variables.
Where the data recipient is applying newer analytical
approaches to shared clinical trial data, resulting publi-
cations should compare and contrast back to the results
obtained from the original clinical trial(s). Possible rea-
sons for differences in results should be described and
differences in assumptions used by the different methods
clarified. An important aspect to consider is the reso-
lution of conflicting results between the original analysis
and any new analyses. During drug licencing, differing
analyses are taken into consideration by the regulatory
authorities in light of which analyses were primary, were
pre-specified as secondary or sensitivity analyses, and
which were done post-hoc. The final interpretation of
benefit-risk is then taken by the drug licensing authority.
If a new analysis potentially alters the benefit-risk profile
of a drug, perhaps in a newly-investigated subgroup, it is
imperative that the methods, assumptions, and possible
reasons for important discrepancies are clearly de-
scribed. The data holder should be informed of the re-
sults, and evaluation of the implications by a licensing
authority might sometimes be required.
Research aiming to replicate and verify the original results
To date, reanalysis of shared clinical trial data with the
primary purpose of replicating and verifying the results
of the primary analysis has been uncommon, though
some examples do exist. Sydes et al [21] report the ex-
perience of the MRC clinical trials unit; of the 103 for-
mal data sharing activities logged in 2012, 2013 and
2014, none aimed to replicate the original analyses.
Strom et al [22] report the experience of an independent
review panel overseeing requests for access to de-
identified patient-level data from clinical trials sponsored
by GlaxoSmithKline. In the first year, 23 requests had
progressed to a signed data-sharing agreement, with only
one of these explicitly identifying concerns about the
way in which a study was analysed and reported and
aiming to reanalyse the data from the study and report
all findings objectively. The results of the reanalysis have
subsequently been published [23].
As noted above, an exact replication of the original re-
sults might not always be possible, for example due to
data privacy provisions. This is particularly problematic
when the primary purpose of the reanalysis is to repli-
cate and verify the original results. If there is likely to be
any impact of data privacy provisions on the analyses
that are to be replicated, the data recipient and data
holder should discuss during the request process how
this issue will be handled.
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When a reanalysis of study data is planned which aims
purely to replicate the results in the original study report,
it is important to ensure that the analysis population, the
outcome measures and the statistical methodology are all
consistent with the original plans. A comparison should
be carried out between any newly derived and the original
derived variables and any discrepancies should be
accounted for, where possible.
It is recommended that if differences are observed that
impact the interpretation of the results, then data recipi-
ents discuss the reanalysis with the authors of the ori-
ginal analyses prior to publication of their findings. This
can help to understand the reason behind any differ-
ences, and hence avoid causing any unnecessary concern
which could arise.
Specific considerations for meta-analysis
With increasing data transparency, data recipients are
increasingly able to conduct meta-analysis (MA) and
network meta-analysis (NMA) using individual patient
data (IPD) rather than using aggregate data obtained
from publications. The use of IPD in MA and NMA
may increase precision of the effects being estimated,
and examination of subgroups across multiple studies
increases power and allows the consistency of effects to
be assessed. In particular, the use of IPD limits possible
ecological bias [24–26]. For an NMA, the use of patient-
level covariates should also allow a better evaluation of
the heterogeneity and inconsistency in the network [27].
There are a number of general guidance documents
which describe good practices for planning, conduct-
ing reporting and interpreting MA [28, 29] and NMA
[30–32]. In MA and NMA there are key assumptions
including exchangeability, homogeneity and similarity
of trials being pooled, and for NMA the consistency
of direct and indirect evidence. Research proposals
for MA and NMA need to describe the clinical evi-
dence forming the basis for the analysis, possible
biases and limitations of the available evidence, the
statistical methods to be used, and a range of sensitivity
analyses that enable the robustness of the results to be
assessed relative to the various assumptions being made.
Bender et al [33] describe sources of multiplicity which
commonly arise in meta-analyses, including multiple out-
comes, multiple interventions, multiple time points, sub-
group analyses and accumulating data.
However there are a number of additional consid-
erations when conducting MA or NMA using IPD
[29, 32, 34, 35]. For example, there may be potential
bias if IPD cannot be made available for all studies
[36]; inconsistencies in IPD may arise when studies
use different variable definitions, or adopt different
randomization and follow-up procedures; statistical
method used (e.g. one-stage versus two-stage models). In
some cases, a combination of aggregate (summary) data
and IPD data may be available for the MA or NMA. There
are different approaches available for combining aggregate
data and IPD in an MA and NMA, with research ongoing
to establish potential biases and limitations in the analyt-
ical approaches [27, 37].
Some data holders require use of a locked analysis sys-
tem, which allows upload but not export of data. This
would not place any limitations on a two-stage analysis
approach in which the IPD are analysed consistently but
separately to produce trial-specific estimates of effects of
interest which are then combined in a weighted average.
However, this could pose challenges for a one-stage ap-
proach where all trials are analysed simultaneously
within a single statistical model. We note that some
sponsors are participating in multi-sponsor environ-
ments (e.g. the Clinical Data Study Request site [38] and
the YODA project [39]) that allow for analyses across
sponsors. Where this is not the case, dialogue with the
various data holders is recommended to seek a collab-
orative solution that is acceptable to all parties. Add-
itionally, a central repository has been proposed for IPD
that have already been collected by collaborative groups
to ensure that these datasets are safeguarded and made
available for use by others [40].
Specific considerations for supplemental analysis
Examples of research objectives in this category include:
 exploring prognostic factors and characterising
disease evolution over time
 evaluating new statistical methods
 understanding relationships between endpoints
 gaining information to inform the design of a future
study
When making any comparison between non-randomized
groups of subjects, the most critical issue to consider will
be the control of bias and confounding. Existing methodo-
logical guidelines for epidemiological analyses can be used
for guidance on available analysis methods, what features
should be pre-specified, and how the results should
be reported [41]. There are a number of areas where
further guidance would be valuable, and we welcome
the strengthening analytical thinking for observational
studies (STRATOS) initiative, a large collaboration of ex-
perts in many different areas of biostatistical research with
the objective to provide accessible and accurate guidance
in the design and analysis of observational studies [42].
When completely new research questions are ad-
dressed, there may be opportunities for confirmatory
analysis with formal multiplicity control as a technique
to control the risk of false positive findings. Even when
more exploratory analyses are planned, pre-specification
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of the objectives and methods is still valuable to aid
interpretation.
When clinical trial data are used for a research ques-
tion that is not directly assessing the randomized inter-
vention, the systematic effect that is introduced by the
randomisation may need to be considered. The interven-
tion assignment may generate spurious relationships, or
mask relationships within the data. It will generally be
important to allow for the intervention assignment by
performing analysis within each arm of the trial, or
restricting the analysis to a single arm. Alternatively the
intervention assignment could be included as a covariate
along with relevant interaction terms in a statistical
model, though this complexity will still need to be ad-
dressed in the interpretation.
Summary
Increased provision of patient-level data from industry
and academic-led clinical trials for secondary research
can benefit future patients and society. The risk of
publication of misleading results and the potential for
unfounded health scares has been highlighted [3]; re-
sponsible data sharing, including transparency of the
research objectives, analysis plans and the results will
support appropriate interpretation and help to address
this risk.
In order to support appropriate interpretation and
limit the risk of misleading findings, analysis of shared
clinical trial data should have a pre-specified analysis
plan. However, it is not generally possible to limit bias
and control multiplicity to the extent that is possible in
the original trial design, conduct and analysis, and this
should be acknowledged and taken into account when
interpreting results. Following the best practices
highlighted in this paper can increase the validity of
these analyses; ensuring there are appropriate planned
statistical analyses, that the existing data can support
these, that results are appropriately presented and inter-
preted, and appropriately disseminated to the research
community. A key issue is that all analyses of shared
clinical trial data essentially share many of the limita-
tions of any post hoc analyses beyond the original speci-
fied analyses. The use of individual patient data in
meta-analysis can provide increased precision and re-
duce bias. Supplemental analyses are subject to many of the
same issues that arise in broader epidemiological analyses.
There are many remaining challenges in achieving
responsible data sharing. The Institute of Medicine con-
clude their comprehensive review of this area by recom-
mending the convening of a multi-stakeholder body to
address the key infrastructure, technological, sustainabil-
ity, and workforce challenges associated with the sharing
of clinical trial data [43].
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